Payment overview · 2025
General Payments
$639.58
33 reported records · 11 companies
Healthcare provider profile · identity verified
Calvin R Jackson
Allopathic & Osteopathic Physicians|Internal Medicine · AUGUSTA, GA · NPI 1740398338
Verified facts
What the public records show
CMS Open Payments records show Calvin R Jackson received $639.58 in general payments during 2025 across 33 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $178.36 | 27.9% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $162.55 | 25.4% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $80.84 | 12.6% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $55.42 | 8.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $36.98 | 5.8% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $34.22 | 5.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.18 | 3.9% | 1 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $21.03 | 3.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.31 | 2.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.65 | 2.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.04 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $639.58 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $162.55 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $140.91 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $80.84 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $62.73 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $55.42 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.56 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $36.98 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $34.22 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $25.18 | 1 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 141 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 108 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 115 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
141 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
78 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
115 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 880 | 232 |
| Atorvastatin Calcium | Atorvastatin Calcium | 499 | 154 |
| Pantoprazole Sodium | Pantoprazole Sodium | 452 | 126 |
| Meloxicam | Meloxicam | 429 | 124 |
| Tramadol Hcl | Tramadol Hcl | 397 | 102 |
| Hydrochlorothiazide | Hydrochlorothiazide | 323 | 83 |
| Gabapentin | Gabapentin | 309 | 66 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 282 | 76 |
| Omeprazole | Omeprazole | 281 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 280 | 77 |
| Simvastatin | Simvastatin | 274 | 77 |
| Metformin Hcl | Metformin Hcl | 253 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 248 | 55 |
| Furosemide | Furosemide | 247 | 63 |
| Losartan Potassium | Losartan Potassium | 239 | 64 |
| Alprazolam | Alprazolam | 227 | 36 |
| Montelukast Sodium | Montelukast Sodium | 183 | 47 |
| Lisinopril | Lisinopril | 182 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 177 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 47 |
| Nifedipine Er | Nifedipine | 174 | 42 |
| Allopurinol | Allopurinol | 171 | 44 |
| Carvedilol | Carvedilol | 169 | 51 |
| Eliquis | Apixaban | 169 | 39 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 154 | 42 |
| Pregabalin | Pregabalin | 147 | 30 |
| Potassium Chloride | Potassium Chloride | 145 | 41 |
| Donepezil Hcl | Donepezil Hcl | 142 | 38 |
| Farxiga | Dapagliflozin Propanediol | 141 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 138 | 42 |
| Jardiance | Empagliflozin | 129 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 118 | 33 |
| Rybelsus | Semaglutide | 115 | 16 |
| Azithromycin | Azithromycin | 111 | 83 |
| Famotidine | Famotidine | 110 | 32 |
| Ozempic | Semaglutide | 108 | 19 |
| Labetalol Hcl | Labetalol Hcl | 104 | 23 |
| Meclizine Hcl | Meclizine Hcl | 101 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 100 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 33 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 100 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 100 | 37 |
| Baclofen | Baclofen | 96 | 25 |
| Celecoxib | Celecoxib | 96 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 32 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 95 | 32 |
| Megestrol Acetate | Megestrol Acetate | 94 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 89 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 18 |
| Januvia | Sitagliptin Phosphate | 87 | 21 |
| Clonidine Hcl | Clonidine Hcl | 85 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 83 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 79 | 25 |
| Glipizide | Glipizide | 78 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 78 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 76 | 57 |
| Mounjaro | Tirzepatide | 75 | suppressed |
| Glipizide Er | Glipizide | 74 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 22 |
| Ezetimibe | Ezetimibe | 71 | 22 |
| Levofloxacin | Levofloxacin | 69 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 13 |
| Kerendia | Finerenone | 67 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 67 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 66 | 13 |
| Temazepam | Temazepam | 66 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 17 |
| Lorazepam | Lorazepam | 65 | 11 |
| Atenolol | Atenolol | 62 | 15 |
| Colchicine | Colchicine | 61 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 20 |
| Diazepam | Diazepam | 60 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 16 |
| Mometasone Furoate | Mometasone Furoate | 57 | 18 |
| Sucralfate | Sucralfate | 57 | 12 |
| Ibuprofen | Ibuprofen | 55 | 17 |
| Levetiracetam | Levetiracetam | 55 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | suppressed |
| Bumetanide | Bumetanide | 54 | 18 |
| Prednisone | Prednisone | 54 | 37 |
| Memantine Hcl | Memantine Hcl | 52 | 12 |
| Clonazepam | Clonazepam | 47 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 46 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 45 | 16 |
| Lovastatin | Lovastatin | 44 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 43 | 13 |
| Glimepiride | Glimepiride | 42 | suppressed |
| Chlorthalidone | Chlorthalidone | 41 | 14 |
| Linzess | Linaclotide | 39 | 11 |
| Naproxen | Naproxen | 39 | suppressed |
| Dutasteride | Dutasteride | 38 | 11 |
| Sertraline Hcl | Sertraline Hcl | 38 | suppressed |
| Fluconazole | Fluconazole | 36 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 34 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 33 | 11 |
| Finasteride | Finasteride | 33 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 21 |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Ketoconazole | Ketoconazole | 28 | suppressed |
| Novolog | Insulin Aspart | 28 | suppressed |
| Telmisartan | Telmisartan | 28 | suppressed |
| Glyburide | Glyburide | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | 12 |
| Torsemide | Torsemide | 21 | suppressed |
| Metaxalone | Metaxalone | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Cephalexin | Cephalexin | 19 | 17 |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Loxapine | Loxapine Succinate | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $639.58 · 33 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, Kerendia, Ozempic, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, Veltassa, XIFAXAN, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error